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Abstract 
Metoclopramide Hydrochloride (MCP), has a short half-life. In order to maintain therapeutic levels in blood, it 
administered in dose of 10-15 mg four times a day. Fluctuation in plasma concentration of drug is commonly 
observed for drugs that are rapidly absorbed and eliminated when used in long term therapy. This attribute 
makes metoclopramide a suitable candidate for controlled release delivery. In this work HPMC K4M was used 
as release rate controlling polymer for the development of controlled release tablet formulation. Experimental 
Design using CCRD was utilized to determine the influence of varying the concentration of different variables 
such as polymer and diluents on the release behavior of the drug from matrix tablets and optimization of 
formulation. Different SR formulation prepared were designed and optimized with the help of software Design 
Expert® version 10.  
------------------------------------------------------------------------ 
* Corresponding author.  
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Using Central Composite Rotatable Design (CCRD), fifteen formulations were selected and prepared using 
HPMC K4M, Avicel PH-102 and Lactose DC as variables. All the trial formulations were evaluated using 
different pharmacotechnical tests including hardness, friability, disintegration, dissolution. Online Dissolution 
apparatus type II and 900 ml different dissolution media in the pH range 1-6.8 and distilled water for 
dissolution. The drug release was studied by applying the dissolution models by DDSolver® software. Hixson-
Crowell model was best fit to the F13 SR formulation. The CCRD experimental design was successfully used in 
optimization of sustained release Metoclopramide HCl formulation.  
Keywords: Metoclopramide HCl (MCP); Sustained Release; Optimization; CCRD; Model Dependent 
approaches; Swelling and Erosion; Stability Study. 
1. Introduction  
Metoclopramide HCl (MCP), a freely water-soluble drug, acts as dopamine receptor antagonist. The relative 
shorter plasma half-life of about 5-6 hours requires small dose of 15-20mg peroral to be administered 3-4 times 
a day [23]. This frequent dosing to overcome plasma level fluctuation, results in extrapyramidal effects. The 
relatively small dose, rapid absorption from intestine, undesirable side effects and shorter half-life forms strong 
basis to develop sustained release formulation of Metoclopramide. Metoclopramide is affected by hepatic first 
pass metabolism which discourages its selection as candidate for sustained release formulation [18]. Modified 
release dosage forms offer an effective means to optimize the bioavailability and plasma drug levels, which 
other-wise results in various problems. Controlled release drug delivery System is one of such attempts being 
made to achieve; control over drug release, drug concentration at target site and optimization of therapeutic 
effects by controlling drug release, dosing frequency and improved patient compliance. Such sustained release 
behavior of the formulation would obviate the secondary effects of the metoclopramide on the central nervous 
system normally encountered with the administration of immediate release formulations. It along with 
decreasing the number of doses improves the patient compliance [32]. Hypromellose or hydroxyl propyl methyl 
cellulose (HPMC) is an odorless, colorless white, fibrous or powder material which is stable at large pH ranging 
from 3-11 [1]. HPMC is a multi-purpose material available in various grades and viscosities which are used in 
different concentrations in formulations for different purposes i.e. coating agent by (Sangalli and his colleagues 
2004).Avecil is commercially available in different particle sizes and moisture grade. Due to variable properties 
Avicel applications ranges from disintegrant and lubricant depending on the case [1]. The aim of this study was 
to evaluate the effect of both the diluents and polymer on the drug release behavior and optimization of 
Metoclopramide HCl from matrix SR oral tablets using CCRD optimization technique.  
2. Materials and Methods 
2.1. Materials 
Metoclopramide HCl (standard obtained from Shaigan Parma (Pvt) limited Pakistan), Avicel PH-102 - (FMC 
Biopolymer, Philadelphia), Magnesium Stearate (Dow Chemical Co., USA), HPMC K4M cps (Dow chemical 
Co., US). All glass wares like Beakers, Funnels, Volumetric Flasks, Pipettes, Graduated Cylinders (Pyrex, 
England). 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2020) Volume 64, No  1, pp 210-221 
212 
 
2.2. Design of the formulations by CCRD 
To formulate the tablets RCCD (Rotatable Central Composite design) was used. The Design Expert® (Version 
10, Stat-Ease Inc., Minneapolis, MN) was used for the performance of statistical analysis. Ranges of three 
independent factors used were (X1) HPMC K4M (15%-50%), (X2) Avicel PH-1O2 (15%-40%), (X3) Lactose 
DC (15%-45%). Disintegration time (R1) hardness (R2), friability (R3) and dissolution (R4) were taken as 
response variables. Formulations were selected on random basis and the results obtained were evaluated as 
shown in the table below[2, 3]. 
Table 1: Independent variables and levels 
Independent variables 
(Factors) 
Levels 
-α 0 +α 
A; Amount of HPMC 
K4M (%) 
15 32.5 50 
B; Amount of 
AvecilPH102 (%) 
15 27.5 40 
C; Amount of Lactose 
DC 
15 30 45 
2.3. Preparation of SR Metoclopramide HCl tablets 
Direct compression method was used after mixing the powder for about 10min in ERWEKA® motor drive type 
AR 403 which is a main drive for ERWEKA® world-wide known all-purpose equipment, to compress the target 
weight with punches having round shape.  
2.4. Evaluation of SR Metoclopramide HCl tablets 
All the tablets formulations compressed were subjected to assess for different pharmacopoeial characteristics 
including hardness [4] , friability [4],  disintegration time, disintegration [5]. The drug release of 
Metoclopramide HCl tablet formulations was evaluated by using USP [5] official method. All the measurements 
were made automatically by software Disso.net at  = 309 nm. 
2.5. Model dependent approaches 
To compare different formulations model dependent approaches are frequently employed and also used in 
optimization process due to differences in release mechanism. The model dependent approaches applied are 
reported in literature [6, 7]. Hixson-Crowell cube root model [7-9]Korsmeyer-peppas model [7, 10]. 
3. Results 
Among fifteen possible combinations the blended mixtures of each runs were selected randomly on the basis of 
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target tablet weight i.e. 200mg given in the table below.  
Table 2: Trial Metoclopramide Formulations Derived from DE using Central Composite Model 
Run 
HPMC 
K4M 
(%) 
Avicel 
PH102 
(%) 
Lactose 
DC 
(%) 
HPMC 
K4M 
(mg) 
Avicel 
PH102 
(mg) 
Lactose 
DC 
(mg) 
Mg. 
Stearate 
(mg) 
MCP 
(mg/tablet) 
Total 
weight 
(mg/tablet) 
10 50 15 45 100 30 90 5 30 255 
13 15 27.5 30 30 55 60 5 30 180 
14 15 15 45 30 30 90 5 30 185 
Compressed formulations were subjected to physicochemical evaluations represented in table 3.  
Table 3: Physicochemical Tests of Metoclopramide Formulations 
  
 
Hardness 
(Kg±SD) 
Friability 
(%) 
Disinte
g. Time 
Shelf Life 
Limits [5]  7-9 Kg <1% (min) (months) 
SR F10 7.62±0.215 0.57 236 60 
F13 8.60±0.113 0.20 258 66 
F14 7.95±0.223 0.33 225 57 
Response surface methodology graphs are sown in figure. 1(a, b, c, d).  
 
Figure 1a: Response surface plot for disintegration time A: 3D surface plot, B: contour plot 
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Figure 1b: Response surface plot for hardness A: 3D surface plot, B: contour plot 
 
Figure 1c: Response surface plot for friability A: 3D surface plot, B: contour plot 
 
Figure 1d: Response surface plot for Dissolution (%) at 12th hour A: 3D surface plot, B: contour plot 
The friability results are shown in table 4.  
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2020) Volume 64, No  1, pp 210-221 
215 
 
Table 4: In Vitro Model Dependent Kinetic Studies of Metoclopramide HCl SR Tablets in Different Media 
 Zero Order 
Model 
First Orders 
Model 
Higuchi Model Hixson- Crowell 
Model 
Korsmeyer –Peppas Model 
 R2 K0 (h-
1) 
R2 K1 (h-
1) 
R2 KH (h-
1/2) 
R2 KHC 
(h1/3) 
R2 n KKP (h-
n) 
Dissolution Medium 1: SR in 0.1NHCl (pH 1.2) 
F-10 0.866
2 
4.484 0.856
5 
0.485 0.9779 27.1123 0.9804 0.0752 0.9186 0.4223 20.5238 
F-13 0.870
3 
4.606 0.867
0 
0.356 0.9855 18.2124 0.9901 0.0503 0.9208 0.5129 18.2347 
F-14 0.864
7 
3.451 0.861
2 
0.338 0.9708 22.1358 0.9755 0.0555 0.9004 0.4557 15.7345 
Dissolution Medium 2: SR in Phosphate Buffer pH 4.5 
F-10 0.837
7 
3.600 0.810
6 
0.421 0.9622 12.3219 0.9752 0.0347 0.9766 0.5003 26.3210 
F-13 0.845
0 
4.652 0.846
9 
0.451 0.9690 10.5620 0.9887 0.0571 0.9852 0.5195 32.9803 
F-14 0.833
4 
3.603 0.825
7 
0.413 0.9440 7.8346 0.9788 0.0438 0.9829 0.5125 26.2206 
Dissolution Medium 3: SR in Phosphate Buffer pH 6.8 
F-10 0.867
1 
3.571 0.845
6 
0.510 0.9122 21.3210 0.9654 0.0605 0.9454 0.4863 40.5096 
F-13 0.880
9 
4.605 0.867
3 
0.495 0.9156 19.8324 0.9848 0.0506 0.9667 0.5006 48.7022 
F-14 0.872
5 
3.542 0.860
5 
0.424 0.9053 26.0872 0.9780 0.0414 0.9589 0.4903 43.4434 
Dissolution Medium 4:SR in Distilled Water 
F-10 0.840
8 
3.126 0.811
1 
0.422 0.9457 15.5679 0.9783 0.0629 0.9403 0.4886 44.3456 
F-13 0.865
4 
4.147 08153 0.466 0.9558 13.6305 0.9925 0.0333 0.9452 0.4958 47.2212 
F-14 0.855
6 
2.128 0.806
7 
0.453 0.9502 11.7322 0.9804 0.0401 0.9308 0.3787 38.3321 
Disintegration time of SR was calculated (table 3). The fig. 1a-1d shows the Response Surface Plots and contour 
plots. Multiple point dissolution of all the SR formulations was performed in different dissolution medium as 
represented in figures. 2a-2d. 
 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2020) Volume 64, No  1, pp 210-221 
216 
 
 
Figure 2: (a-d): Percentage Release of Metoclopramide HCl from SR Tablets at pH 1.2, 4.5, 6.8 and Distilled 
Water (n=12) 
Table 5: Analysis of variance for disintegration 
Source Sum of Squares df Mean Square F Value p-value Prob> F  
Model 1.470E+005 9 16330.17 23.29 0.0015 significant 
A-HPMC K4M 1.014E+005 1 1.014E+005 144.55 < 0.0001  
B-Avicel PH102 752.34 1 752.34 1.07 0.3477  
C-Lactose DC 6273.72 1 6273.72 8.95 0.0304  
AB 1754.47 1 1754.47 2.50 0.1745  
AC 3439.11 1 3439.11 4.90 0.0776  
BC 183.16 1 183.16 0.26 0.6310  
A2 2507.90 1 2507.90 3.58 0.1172  
B2 45.41 1 45.41 0.065 0.8093  
C2 1355.52 1 1355.52 1.93 0.2231  
Residual 3505.82 5 701.16    
Cor Total 1.505E+005 14     
Table 6: Analysis of variance for Hardness 
Source Sum of Squares df Mean Square F Value p-value Prob> F  
Model 70.37217 9 7.81913 7.221798 0.021171 significant 
A-HPMC K4M 11.59386 1 11.59386 10.70816 0.022141  
B-Avicel PH102 34.31932 1 34.31932 31.69754 0.00245  
C-Lactose DC 2.834052 1 2.834052 2.617548 0.166612  
AB 0.234173 1 0.234173 0.216284 0.661437  
AC 1.006224 1 1.006224 0.929355 0.379306  
BC 2.076211 1 2.076211 1.917602 0.224729  
A^2 1.078687 1 1.078687 0.996282 0.364036  
B^2 0.154013 1 0.154013 0.142247 0.721535  
C^2 8.778887 1 8.778887 8.108235 0.035929  
Residual 5.413562 5 1.082712    
Cor Total 75.78573 14     
The results of kinetic studies are shown in (table 4). The tables 5-8 show the analysis of variance for 
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disintegration, hardness, Friability and dissolution respectively.  
Table 7: Analysis of variance for Friability 
Source Sum of Squares df Mean Square F Value p-value Prob> F  
Model 0.89 9 0.099 9.83 0.0108 significant 
A-HPMC K4M 0.14 1 0.14 13.93 0.0135  
B-Avicel PH102 0.19 1 0.19 18.45 0.0077  
C-Lactose DC 0.097 1 0.097 9.64 0.0267  
AB 6.553E-003 1 6.553E-003 0.65 0.4568  
AC 0.089 1 0.089 8.81 0.0312  
BC 0.100 1 0.100 9.89 0.0255  
A2 6.810E-003 1 6.810E-003 0.68 0.4486  
B2 0.073 1 0.073 7.26 0.0431  
C2 5.022E-004 1 5.022E-004 0.050 0.8322  
Residual 0.050 5 0.010    
Cor Total 0.94 14     
Table 8: Analysis of variance for Dissolution % at 12th hour 
Source Sum of Squares df Mean Square F Value p-value Prob> F  
Model 221.76 9 24.64 20.82 0.0019 significant 
A-HPMC K4M 172.88 1 172.88 146.11 < 0.0001  
B-Avicel PH102 0.020 1 0.020 0.017 0.9019  
C-Lactose DC 0.21 1 0.21 0.17 0.6932  
AB 20.63 1 20.63 17.44 0.0087  
AC 3.24 1 3.24 2.74 0.1590  
BC 2.26 1 2.26 1.91 0.2254  
A2 5.28 1 5.28 4.46 0.0884  
B2 3.72 1 3.72 3.15 0.1363  
C2 0.93 1 0.93 0.79 0.4152  
Residual 5.92 5 1.18    
Cor Total 227.68 14     
 
4. Discussion 
Optimization technique was employed to prepare 15 formulations. Out of fifteen designed formulations one SR 
formulations (table 2) was selected having three variables. Central Composite Design was also effectively used 
for the optimization of formulations [11-13]. Rotthauser and his colleagues in 1998 used Central Composite 
Design for optimization of effervescent tablet formulation to evaluate the effect of lubricants and compressional 
force on physical characteristics of these tablets [2]. Magnesium Stearate (5%) was kept constant for all 
formulations. The description of the effect of formulation factors on the responses with the help of empirical 
models (linear and quadratic) is one of  the major advantages of the response surface design [14]. The three-
dimensional response surface plots and the contour plots are portrayed in figs. 1 (a, b, c). These plots show that 
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effect of two factors on a response at the same time, showing increase in the disintegration time with the 
increase of HPMC and MCC with only a little effect on the overall hardness and friability of the tablets.  
Different quality attributes of all the compressed trial formulations such as, hardness, disintegration time and 
dissolution were evaluated according to the USP specifications [15]. The results are shown in table 3. Nyqvist 
and his colleagues in 1982 also evaluated the physicochemical properties of tablets prepared by using Avicel PH 
102, HPMC K4M and magnesium Stearate as excipients showed excellent physicochemical properties [16]. All 
the SR formulations were compressed with good hardness having the values of 8-10 kg, and friability was also 
found less than 1% (table 3)[17]. Shah and his colleagues in 2011 prepared fast dissolving Metoclopramide 
tablets using crospovidone, croscarmellose sodium and sodium starch glycolate by direct compression method 
and performed pharmacopoeial quality assessment tests. The hardness and % drug contents were in the range of 
8-10 Kg/cm² and 98.54% to 101.23% respectively while % friability for all the formulations was found to be 
within limits (<1) [18].  The disintegration time of trial formulations were also found to be within limits. SR 
formulation took more than four hours to disintegrate (table 3).  In SR formulations, presence of polymer HPMC 
K4M in the concentration of 22-43.46% increased the disintegration time (table3). During the development of 
formulations, dissolution testing can help in the selection of excipients as well as optimization of the 
manufacturing process and enable formulation of the test product to match the release of the reference product 
[19]. In vitro dissolution test is performed to measure the amount of drug released into the dissolution medium 
within specified time. [20]. In the present study multiple point dissolution test of Metoclopramide HCl was 
conducted in four different dissolution media i.e. 0.1 N HCl, phosphate buffer pH 4.5, 6.8 and distilled water 
(fig. 2-5). SR formulations (F10, F13, F14) containing higher concentrations of HPMC K4M (40-48%) F13 
showed further decrease in the overall drug release rate compared to the rest of the two (figs. 2a-2d). Tandya 
and his colleagues in 2007 reported list of polymers which can be used in controlled release formulations [21].  
4.1. Model dependent approaches  
In order to describe the drug release from Metoclopramide HCl to get optimized formulation (SR) various 
mathematical model like Zero Order, First Order, Higuchi’s equation, Hixson-Crowell and Korsmeyer&Peppas 
were applied to the in vitro release data obtained in various dissolution media (0.1N HCl, phosphate buffer pH 
4.5, 6.8 and distilled water). Criterion of selecting the most appropriate model was based on the best goodness 
of fit. Correlations (R2) of individual batch with applied equations are given in table 5. The release rates were 
calculated from the slope of the appropriate plots and regression coefficient was determined (tables 4). When SR 
formulations were subjected to Zero Order model, the values of R2 in 0.1N HCl, pH 4.5 and 6.8 and distilled 
water came out to be very poor (see tables 4).SR formulations are showing higher values for all the test media 
i.e. 0.1N HCl, pH 4.5 and 6.8 and distilled water and showing better compliance than other formulations with 
Zero Order model. Reddy and his colleagues (2003) reported that once-daily sustained-release matrix tablets of 
HPMC K4M based Nicorandil did not follow zero order release pattern [22]. The First order describes that the 
rate of drug release from systems is concentration dependent. The SR formulations are not following First Order 
release pattern. Hassan and his colleagues in 2003 reported similar results (0.987) for the Metoclopramide HCl 
tablets [23]. Mandal and Pal (2008) reported that the formulations of metformin HCl formulated using different 
grades of HPMC (HPMC K4M, K15M, K100M) did not follow first order release pattern [24]. However, the 
coefficient of correlation values of F10 and F14 formulations were comparatively lower than that of F13 
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formulations as presented in tables 5. Similar Higuchi kinetics were reported by Merchant and his colleagues in 
2006 in the preparation of once daily tablet formulation of cefpodoxime from HPMC by direct compression 
[25]. Another study by Shoaib and his colleagues in 2010 reported R2 values of 0.988 for slow release 
formulation Famotidine HPMC K4M matrix [26]. Abdel-Rahman and his colleagues in 2009 prepared HPMC 
based matrix tablets of Metoclopramide HCl and reported the R2 values 0.998 [27]. Hassan and his colleagues in 
2003 reported similar Higuchi findings (R2 = 0.9929) and found it best fit for the release data of 
Metoclopramide HCl controlled release tablets [28]. The SR Metoclopramide HCl formulation (F13) was 
observed to show best linearity and compliance with Hixson-Crowell model. The value of R2 were found out to 
be 0.999 (0.1NHCl), 0.995, (phosphate buffer pH 4.5), 0.990 (phosphate buffer pH 6.8) and 0.996 (distilled 
water). Whereas the value of R2 for intermediate and immediate formulations in the same media was 
comparatively lower than that of slow release formulations (tables 5). Similar findings were reported by Shoaib 
and his colleagues in 2006 prepared Ibuprofen HPMC matrix tablets and obtained R2 value of 0.996 [29]. In 
another study, Sankar and his colleagues in 2010 also obtained similar results i.e. R2 = 0.9999 for zidovudine 
HPMC matrix tablets [30, 31]. To find the drug release mechanism the in vitro release data were applied to 
Korsmeyer-Peppas model (KorsmeyerPeppas, 1983). The corresponding plot of log cumulative % drug release 
vs time for all the trial formulations indicated good linearity as mentioned in table 5. Similar R2 results (0.9959) 
were obtained by Radhika and his colleagues 2005 using HPMC as polymer in glipzide tablets formulation 
development [32].  The value of release exponent (n) for SR formulations was following non-Fickian diffusion 
or anomalous release pattern (table 4). Venkatesh and his colleagues in 2010 used HPMC as polymer in the 
preparation of Prochlorperazine Maleate Sustained Release Tablets and found n values less than 0.5 [33]. In 
another study Korsmeyer–Peppas Model was applied to HPMC polymer based Metoclopramide tablets by 
Shiyani and his colleagues in 2008, the value of n was 0.266 showing Quasi –Fickian diffusion [34, 35]. 
5. Conclusion 
By applying optimization technique different formulations of Metoclopramide Hydrochloride with varying 
release rates were developed. Multiple point dissolution studies using different dissolution media such as 0.1 N 
HCl, phosphate buffer pH 4.5, 6.8, distilled water was performed using USP Dissolution apparatus II (Paddle 
Method). Models such as Zero Order, First Order, Higuchi Model and Korsmeyer-Peppas Models were used to 
study the dissolution rate kinetics. The best fit models were Hixson-Crowell for SR formulation F13.  
Acknowledgment 
Financial support from HEC Pakistan is greatly acknowledged.  
References 
[1]. R. C. Rowe, P. J. Sheskey, S. C. Owen, and A. P. Association, Handbook of pharmaceutical excipients. 
Pharmaceutical press London, 2006. 
[2]. B. Rotthäuser, G. Kraus, and P. C. Schmidt, "Optimization of an effervescent tablet formulation 
containing spray dried L-leucene glycol 6000 as lubricant using a  central composite design " Eur J 
Pharm Biopharm, vol. 46, no. 1, pp. 85-94, 1998. 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2020) Volume 64, No  1, pp 210-221 
220 
 
[3]. G. E. P. Box and D. W. Behnken, "Some new three level designs for the study of quantitative 
variables," Technometrics, vol. 2 no. 4, pp. 455–475, 1960. 
[4].  (2004). Resistance to crushing of tablets  
[5]. USP, Ed. "United States Pharmacopoeia 30 and National Fomulary 25." The United States 
Pharmacopoeial Convention,CD ROM, 2007. 
[6]. T. Higuchi, "Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid 
drugs dispersed in solid matrices," J. Pharm. Sci vol. 52 no. 12, pp. 1145–1149, 1963. 
[7]. P. Costa and J. M. S. Lobo, "Modeling and comparison of Dissolution profile," European Journal of 
Pharmaceutical Sciences vol. 13, no. 2, pp. 123-133, 2001. 
[8]. A. W. Hixson and J. H. Crowell, "Dependence of reaction velocity upon surface and agitation," Ind. 
Eng. Chem, vol. 23 no. 8, pp. 923–931, 1931  
[9]. H. M. Abdou, "Theory of Dissolution " in Dissolution ,Bioavailibility, and Bioequivalence, A. 
Gennaro, B. Migdalof, G. L. Hassert, and T. Medwick, Eds., ed. Easton ,Pennsylvnia 425: Mack 
Publishing Company 1989. 
[10]. R. W. Korsmeyer, R. Gurny, E. M. Doelker, P. Buri, and N. A. Peppas, "Mechanism of solute release 
from porous hydrophilic polymers," Int. J.Pharm, vol. 15, pp. 25–35, 1983. 
[11]. N. Aslan, "Application of response surface methodology and central composite rotatable design for 
modeling and optimization of a multi gravity separator for chromite concentration," Powder 
Technology, vol. 185, pp. 80-86, 2008. 
[12]. S. Schiermeier and P. C. Schmidt, "Fast dispersible Ibuprofen tablets," European Journal of 
Pharmaceutical Sciences vol. 15, pp. 295-305, 2002. 
[13]. S. G. Late, Y. Y. Yu, and A. K. Banga, "Effect of disintegration-promoting agent, lubricants and 
moisture treatment on optimized fast disintegrating tablets," Internation Journal  of Pharmaceutics, vol. 
365, pp. 4-11, 2009. 
[14]. G. S. Rekhi, R. V. Nellore, A. S. Husain, L. G. Tillman, H. J. Malinowski, and L. L. Ausberger, 
"Identification of critical formulations and processing variables for metoprolol tartrate extended release 
(ER) matrix tablets," Journal of Controlled Release, vol. 59, no. 3, pp. 327-342, 1999. 
[15]. U. P. XXVIII, " Rockville, MD, USA," Pharmacopeial Convention pp. pp. 19, .2412, 2745, 2005. 
[16]. H. Nyqvist, M. Nicklasson, and P. Lungren, "Studies on the physical properties of tablets and tablet 
excipients.V. Film coating for protection of a light-sensitive tablet formulation," Acta Pharmaceutica 
Suecica, vol. 19, p. 223, 1982. 
[17]. U. Convention, "United States Pharmacopoeia dispensing information: USP DI. United States 
Pharmacopoeial Convention " 1997. 
[18]. V. Shah, S. S. Patel, R. K. Jatav, A. Jain, and R. V. S. Int, "Formulation and evalution of mouth 
dissolving tablets of metoclopramide hydrochloride by direct compression technique," International  
Journal of  Drug Discovery and  Herbal Research (IJDDHR), vol. 1, no. 2, pp. 100-103, 2011. 
[19]. N. Yuksel, A. E. Kanik, and T. Baykara, "Comparison of in vitro dissolution profiles by ANOVA-
based model dependent and independent methods," International Journal of Pharmaceutics, vol. 209, 
no. 1-2, pp. 57-67, 2000. 
[20].  (1997). Guidance for Industry Extended release oral dosage forms: development, evaluation and 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2020) Volume 64, No  1, pp 210-221 
221 
 
applications of in vitro/in vivo correlations.  
[21]. A. Tandya, R. Mammuucari, F. Dehghani, and N. R. Foster, "Danse gas processing of polymeric 
controlled release formulations," International  Journal of Pharmaceutics, vol. 328, no. 1-11, 2007. 
[22]. K. R. Reddy, S. Mutalik, and S. Reddy, "Once-daily Sustained Release Matrix Tablets of 
Nicorandil:Formulation and In Vitro Evaluation," AAPS PharmSciTech, vol. 4, no. 4, p. E61, 2003. 
[23]. E. I. Hasan, B. I. Amrob, T. Arafatc, and A. A. Badwan, "Assessment of a controlled release 
hydrophilic matrix formulation for metoclopramide HCl," European Journal of Pharmaceutics and 
Biopharmaceutics, vol. 55 pp. 339–344, 2003. 
[24]. U. Mandal and T. K. Pal, "Sustained release of metformin HCl from hydroxy propyl methyl cellulose 
matrices: Formulation and in vitro evaluation," Asian J. Chem, vol. 20, no. 2, pp. 1163-1174, 2008. 
[25]. H. A. Merchant, H. M. Shoaib, J. Tazeen, and R. I. Yousaf, "Once-Daily Tablet Formulation and In 
Vitro Release Evaluation of Cefpodoxime Using Hydroxypropyl Methylcellulose: A Technical Note," 
AAPS PharmSciTech, vol. 7, no. 3, pp. E1-E5, 2006. 
[26]. M. H. Shoaib et al., "Development and Evaluation of Hydrophilic Colloid Matrix of Famotidine 
Tablets," AAPS PharmSciTech, vol. 11, no. 2, pp. 708-718, 2010. 
[27]. S. I. Abdel-Rahman, G. M. Mahrous, and M. El-Badry, "Preparation and comparative evaluation of 
sustained release metoclopramide hydrochloride matrix tablets," Saudi Pharmaceutical Journal, vol. 17, 
no. 4, pp. 283-288, 2009. 
[28]. E. Hasan, B. Amro, T. Arafat, and A. Badwan, "Assessment of a controlled release hydrophilic matrix 
formulation for metoclopramide HCl," Eur J Pharm Biopharm, vol. 55, no. 3, pp. 339-44, 2003. 
[29]. M. H. Shoaib, J. Tazeen, H. A. Merchant, and R. I. Yousaf, "Evaluation of drug release kinetics fro 
ibuprofen matrix tablets using HPMC," Pak. J. Pharm. Sci vol. 19, no. 2, pp. 119-124, 2006. 
[30]. V. Sankar, K. Ruckmani, K. Velayutham, and M. Nithyananth, "Comparative evaluation of zidovudine 
tablets formulated using natural andsemi synthetic binder," Acta Pharmaceutica Sciencia vol. 52, pp. 
263-268, 2010. 
[31]. J. E. Polli, G. S. Rekhi, L. L. Augsburger, and V. P. Shah, "Methods to compare dissolution profiles 
and a rationale for wide dissolution specifications for metoprolol tartrate tablets," J Pharm Sci, vol. 86, 
no. 6, pp. 690-700, 1997. 
[32]. P. R. Radhika, T. K. Pala, and T. S. Kumar, "Formulation and Evaluation of Sustained Release Matrix 
Tablets of Glipizide," Iranian Journal of Pharmaceutical Sciences, vol. 5, no. 4, pp. 205-214, 2009. 
[33]. D. N. Venkatesh, S. Sankar, S. N. Meyyanathan, K. Elango, B. Suresh, and K. Santhi, "Design and 
Development of Prochlorperazine Maleate Sustained Release Tablets: Influence of Hydrophilic 
Polymers on the Release rate and In vitro Evaluation," International Journal of Pharmaceutical 
Sciences and Nanotechnology, vol. 3, no. 2, 2010. 
[34]. B. Shiyani, S. Gattani, and S. Surana, "Formulation and Evaluation of Bi-layer Tablet of 
Metoclopramide Hydrochloride and Ibuprofen," AAPS PharmSciTech, vol. 9 no. 3, pp. 818–827, 2008. 
[35]. S. Basak, B. J. Reddy, and K. L. Mani, "Formulation and release behaviour of sustained release 
ambroxol hydrochloride HPMC matrix tablet," Indian Journal of Pharmaceutical Sciences, vol. 68, no. 
5, pp. 594-598, 2006. 
